NCT06619275

Ripretinib (QINLOCK®) According to Current SmPC

Ripretinib in Patients With Previously Treated Advanced Gastrointestinal Stromal Tumor (GIST): a Prospective, Longitudinal, Multicenter, Observational Study in Germany

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10 (actual)
• Sponsor: iOMEDICO AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective, observational study INTEREST is to collect real-world data on ripretinib treatment in a broad patient population in Germany. Ripretinib will be administered according to the current SmPC. Thus, INTEREST will evaluate for the first time ripretinib in GIST patients in a real-world setting in Germany. The main questions the study aims to answer are: * Evaluate quality of live (QoL) using the questionnaire EQ-5D-5L to gain knowledge about how ripretinib treatment affects GIST patients' well-being (change compared to Baseline, Time to Deterioration) * Assessment of effectiveness in routine treatment (Progression-Free Survival, Overall Survival, Best Response, Overall Response Rate, Disease Control Rate * Assessment of drug safety * Assessment of parameters of physicians\' treatment decision making * Description of treatment reality in detail

Conditions

• GIST - Gastrointestinal Stromal Tumor

Interventions

Type	Name	Description
DRUG	Ripretinib	Switch-Control Tyrosine Kinase Inhibitor

Timeline

• Start date: 2024-10-17
• Primary completion: 2025-08-15
• Completion: 2025-09-15
• First posted: 2024-10-01
• Last updated: 2025-12-05

Locations

1 site across 1 country: Germany